USD 126.2
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| ITCI | -0.0 | -1.4 | 45.5 | 61.1 | 68.4 | 93.7 | 212.8 | 396.3 | 525.1 | 741.3 |
| S&P 500 | 1.0 | 3.7 | 2.1 | 2.3 | 8.2 | 25.4 | 31.0 | 80.6 | 196.5 | 33856.2 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | ITCI |
| name | Intra-Cellular Therapies, Inc. |
| price | 126.2 |
| changes percentage | -0.0475 |
| change | -0.06 |
| day low | 126.16 |
| day high | 126.735 |
| year high | 128 |
| year low | 62.78 |
| market cap | 13407992800 |
| price avg 50 | 88.9494 |
| price avg 200 | 76.93875 |
| exchange | NASDAQ |
| volume | 5897368 |
| avg volume | 1697706 |
| open | 126.65 |
| previous close | 126.26 |
| eps | -0.87 |
| pe | -145.06 |
| earnings announcement | 2025-02-20T13:30:00.000+0000 |
| shares outstanding | 106244000 |
| timestamp | 2025-01-17 21:00:01 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001567514 | |||
| revenue | 464370000 | 249132000 | 86.40 |
| gross profit | 430625000 | 228689000 | 88.30 |
| gross profit ratio | 0.93 | 0.92 | 1.02 |
| research and development expenses | 180142000 | 134715000 | 33.72 |
| operating expenses | 590006000 | 492315000 | 19.84 |
| interest income | 20343000 | 7376000 | 175.80 |
| interest expense | 0 | 7376000 | -100.00 |
| ebitda | -158853000 | -262970000 | 39.59 |
| ebitdaratio | -0.34 | -1.06 | 67.67 |
| operating income | -159381000 | -263626000 | 39.54 |
| operating income ratio | -0.34 | -1.06 | 67.57 |
| net income | -139674000 | -256256000 | 45.49 |
| net income ratio | -0.3 | -1.03 | 70.76 |
| eps | -1.46 | -2.72 | 46.32 |
Revenue Growth: revenue increased to 464 million in 2023 from 249 million in 2022 representing a change of 86.4%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 431 million in 2023 from 229 million in 2022 representing a change of 88.3%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 180 million in 2023 from 135 million in 2022 representing a change of 33.72%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
Earnings per Share (EPS): EPS increased to -1.46 in 2023 from -1.46 in 2022 representing a change of 46.32%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Operating Expenses: Operating Expenses increased to 590 million in 2023 from 492 million in 2022 representing a change of 19.84%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -159 million in 2023 from -263 million in 2022 representing a change of 39.59%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to -159 million in 2023 from -264 million in 2022 representing a change of 39.54%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -140 million in 2023 from -256 million in 2022 representing a change of 45.49%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001567514 | |||
| revenue | 175159000 | 161388000 | 8.53 |
| gross profit | 159855000 | 150034000 | 6.55 |
| gross profit ratio | 0.91 | 0.93 | -1.83 |
| research and development expenses | 66819000 | 56183000 | 18.93 |
| operating expenses | 198704000 | 177757000 | 11.78 |
| interest income | 12899000 | 11560000 | 11.58 |
| interest expense | 0 | 0 | NaN |
| ebitda | -38849000 | -27594000 | -40.79 |
| ebitdaratio | -0.22 | -0.17 | -29.72 |
| operating income | -38849000 | -27723000 | -40.13 |
| operating income ratio | -0.22 | -0.17 | -29.12 |
| net income | -26324000 | -16219999 | -62.29 |
| net income ratio | -0.15 | -0.1 | -49.53 |
| eps | -0.25 | -0.16 | -56.25 |
Revenue Growth: revenue increased to 175 million in 2024Q3 from 161 million in 2024Q2 representing a change of 8.53%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 160 million in 2024Q3 from 150 million in 2024Q2 representing a change of 6.55%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 67 million in 2024Q3 from 56 million in 2024Q2 representing a change of 18.93%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -39 million in 2024Q3 from -28 million in 2024Q2 representing a change of -40.79%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -39 million in 2024Q3 from -28 million in 2024Q2 representing a change of -40.13%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -26 million in 2024Q3 from -16 million in 2024Q2 representing a change of -62.29%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Operating Expenses: Operating Expenses increased to 199 million in 2024Q3 from 178 million in 2024Q2 representing a change of 11.78%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Earnings per Share (EPS): EPS increased to -0.25 in 2024Q3 from -0.25 in 2024Q2 representing a change of -56.25%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001567514 | |||
| total assets | 728295000 | 754780000 | -3.51 |
| total liabilities | 136871000 | 98710000 | 38.66 |
| total equity | 591424000 | 656070000 | -9.85 |
| cash and cash equivalents | 147767000 | 148615000 | -0.57 |
| short term investments | 350174000 | 443290000 | -21.01 |
| long term investments | 0 | 0 | NaN |
| total current assets | 667799000 | 737957000 | -9.51 |
| total non current assets | 60496000 | 16823000 | 259.60 |
| total current liabilities | 123545000 | 83236000 | 48.43 |
| total non current liabilities | 13326000 | 15474000 | -13.88 |
| common stock | 10000 | 9000 | 11.11 |
| retained earnings | -1617160000 | -1477486000 | -9.45 |
| total debt | 16938000 | 20041000 | -15.48 |
Total Assets: Total Assets decreased to 728 million in 2023 from 755 million in 2022 representing a change of -3.51%. Suggesting a decrease in asset holdings.
Total Liabilities: Total Liabilities increased to 137 million in 2023 from 99 million in 2022 representing a change of 38.66%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to 591 million in 2023 from 656 million in 2022 representing a change of -9.85%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 148 million in 2023 from 149 million in 2022 representing a change of -0.57%. This indicates a decrease in available liquid assets.
Short Term Investments: Short Term Investments decreased to 350 million in 2023 from 443 million in 2022 representing a change of -21.01%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 668 million in 2023 from 738 million in 2022 representing a change of -9.51%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 124 million in 2023 from 83 million in 2022 representing a change of 48.43%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -1,617 million in 2023 from -1,477 million in 2022 representing a change of -9.45%. This indicates an accumulated losses.
Common Stock: Common Stock increased to 0 in 2023 from 0 in 2022 representing a change of 11.11%. This indicates an increase in ownership interest.
Total Debt: Total Debt decreased to 17 million in 2023 from 20 million in 2022 representing a change of -15.48%. This indicates a reduction in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001567514 | |||
| total assets | 1324445000 | 1320504000 | 0.30 |
| total liabilities | 179619000 | 175892000 | 2.12 |
| total equity | 1144826000 | 1144612000 | 0.02 |
| cash and cash equivalents | 464312000 | 695056000 | -33.20 |
| short term investments | 542250000 | 329601000 | 64.52 |
| long term investments | 0 | 0 | NaN |
| total current assets | 1271731000 | 1264251000 | 0.59 |
| total non current assets | 52714000 | 56252999 | -6.29 |
| total current liabilities | 166113000 | 161775000 | 2.68 |
| total non current liabilities | 13506000 | 14116999 | -4.33 |
| common stock | 11000 | 11000 | 0.00 |
| retained earnings | -1674951000 | -1648627000 | -1.60 |
| total debt | 17709000 | 18288000 | -3.17 |
Total Assets: Total Assets increased to 1,324 million in 2024Q3 from 1,321 million in 2024Q2 representing a change of 0.3%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 1,145 million in 2024Q3 from 1,145 million in 2024Q2 representing a change of 0.02%. This indicates an increase in shareholders' equity.
Short Term Investments: Short Term Investments increased to 542 million in 2024Q3 from 330 million in 2024Q2 representing a change of 64.52%. This indicates an increase in short-term investment holdings.
Total Current Assets: Total Current Assets increased to 1,272 million in 2024Q3 from 1,264 million in 2024Q2 representing a change of 0.59%. This indicates a better liquidity position.
Total Debt: Total Debt decreased to 18 million in 2024Q3 from 18 million in 2024Q2 representing a change of -3.17%. This indicates a reduction in overall debt burden.
Total Liabilities: Total Liabilities increased to 180 million in 2024Q3 from 176 million in 2024Q2 representing a change of 2.12%. This indicates an increase in overall liabilities.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 464 million in 2024Q3 from 695 million in 2024Q2 representing a change of -33.2%. This indicates a decrease in available liquid assets.
Total Current Liabilities: Total Current Liabilities increased to 166 million in 2024Q3 from 162 million in 2024Q2 representing a change of 2.68%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -1,675 million in 2024Q3 from -1,649 million in 2024Q2 representing a change of -1.6%. This indicates an accumulated losses.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001567514 | |||
| net change in cash | -848000 | 56600000 | -101.50 |
| operating cash flow | -124199000 | -270186000 | 54.03 |
| free cash flow | -124468000 | -270964000 | 54.06 |
| capital expenditure | -269000 | -778000 | 65.42 |
| depreciation and amortization | 528000 | 656000 | -19.51 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 52832000 | 43013000 | 22.83 |
| accounts payables | 1057000 | 1704000 | -37.97 |
| inventory | -26348000 | -15972000 | -64.96 |
| acquisitions net | 0 | 127594999 | -100.00 |
| investments in property plant and equipment | -269000 | -778000 | 65.42 |
| net cash used for investing activites | 105541000 | -128373000 | 182.21 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 17810000 | 433718000 | -95.89 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 17810000 | 455159000 | -96.09 |
| cash at end of period | 149517000 | 150365000 | -0.56 |
| accounts receivables | -38829000 | -55033000 | 29.44 |
| cash at beginning of period | 150365000 | 93765000 | 60.36 |
Net Change in Cash: Net Change in Cash decreased to -1 million in 2023 from 57 million in 2022 representing a change of -101.5%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Capital Expenditure: Capital Expenditure increased to 0 million in 2023 from -1 million in 2022 representing a change of 65.42%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Stock-Based Compensation: Stock-Based Compensation increased to 53 million in 2023 from 43 million in 2022 representing a change of 22.83%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Receivables: Accounts Receivables increased to -39 in 2023 from -55 million in 2022 representing a change of 29.44%. This suggests that the company is less capable of collecting payments from its customers.
Operating Cash Flow: Operating Cash Flow increased to -124 million in 2023 from -270 million in 2022 representing a change of 54.03%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -124 million in 2023 from -271 million in 2022 representing a change of 54.06%. This indicates an increase in cash generated after accounting for capital expenditures.
Accounts Payables: The absolute value of Accounts Payables decreased to 1 million in 2023 from 2 million in 2022 representing a change of -37.97%. This indicates that the company has reduced its outstanding obligations to its suppliers.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001567514 | |||
| operating cash flow | -26525000 | 542000 | -4993.91 |
| free cash flow | -27221000 | 489000 | -5666.67 |
| capital expenditure | -696000 | -53000 | -1213.21 |
| depreciation and amortization | 138000 | 129000 | 6.98 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 17489000 | 16370000 | 6.84 |
| accounts receivables | 106000 | -14557000 | 100.73 |
| accounts payables | -7210000 | 6016000 | -219.85 |
| inventory | -1374000 | -1877000 | 26.80 |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -696000 | -53000 | -1213.21 |
| net cash used for investing activites | -209203000 | 7766000 | -2793.83 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | -12082000 | 545179000 | -102.22 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 6734000 | 545179000 | -98.76 |
| net change in cash | -228994000 | 553487000 | -141.37 |
| cash at end of period | 466062000 | 695056000 | -32.95 |
| cash at beginning of period | 695056000 | 141569000 | 390.97 |
Net Change in Cash: Net Change in Cash decreased to -229 million in 2024Q3 from 553 million in 2024Q2 representing a change of -141.37%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to -27 million in 2024Q3 from 1 million in 2024Q2 representing a change of -4993.91%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -27 million in 2024Q3 from 0 million in 2024Q2 representing a change of -5666.67%. This indicates a decrease in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation increased to 17 million in 2024Q3 from 16 million in 2024Q2 representing a change of 6.84%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 7 million in 2024Q3 from 6 million in 2024Q2 representing a change of -219.85%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables increased to 0 in 2024Q3 from -15 million in 2024Q2 representing a change of 100.73%. This suggests that the company is less capable of collecting payments from its customers.
Capital Expenditure: Capital Expenditure decreased to -1 million in 2024Q3 from 0 million in 2024Q2 representing a change of -1213.21%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 4.84 | 2.65 | 82.83 |
| net income per share | -1.46 | -2.72 | 46.54 |
| operating cash flow per share | -1.3 | -2.87 | 54.91 |
| free cash flow per share | -1.3 | -2.88 | 54.94 |
| cash per share | 5.19 | 6.29 | -17.48 |
| book value per share | 6.17 | 6.98 | -11.58 |
| tangible book value per share | 6.17 | 6.98 | -11.58 |
| shareholders equity per share | 6.17 | 6.98 | -11.58 |
| interest debt per share | 0.18 | 0.29 | -39.40 |
| market cap | 6867049430.98 | 4976949776.4 | 37.98 |
| enterprise value | 6736220430.98 | 4848375776.4 | 38.94 |
| pe ratio | -49.16 | -19.42 | -153.14 |
| price to sales ratio | 14.79 | 19.98 | -25.98 |
| pocfratio | -55.29 | -18.42 | -200.16 |
| pfcf ratio | -55.17 | -18.37 | -200.37 |
| pb ratio | 11.61 | 7.59 | 53.06 |
| ptb ratio | 11.61 | 7.59 | 53.06 |
| ev to sales | 14.51 | 19.46 | -25.46 |
| enterprise value over ebitda | -42.41 | -18.44 | -130.00 |
| ev to operating cash flow | -54.24 | -17.94 | -202.25 |
| ev to free cash flow | -54.12 | -17.89 | -202.46 |
| earnings yield | -0.02 | -0.05 | 60.50 |
| free cash flow yield | -0.02 | -0.05 | 66.71 |
| debt to equity | 0.03 | 0.03 | -6.25 |
| debt to assets | 0.02 | 0.03 | -12.41 |
| net debt to ebitda | 0.82 | 0.49 | 68.45 |
| current ratio | 5.41 | 8.87 | -39.03 |
| interest coverage | 0 | -35.74 | 100.00 |
| income quality | 0.89 | 1.05 | -15.66 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.68 | 1.1 | -37.57 |
| research and ddevelopement to revenue | 0.39 | 0.54 | -28.26 |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.0 | -0.0 | 24.78 |
| capex to revenue | 0.0 | 0.0 | -81.45 |
| capex to depreciation | 0.51 | 1.19 | -57.04 |
| stock based compensation to revenue | 0.11 | 0.17 | -34.10 |
| graham number | 14.22 | 20.68 | -31.25 |
| roic | -0.26 | -0.39 | 32.05 |
| return on tangible assets | -0.19 | -0.34 | 43.51 |
| graham net net | 4.72 | 5.97 | -20.98 |
| working capital | 544254000 | 654721000 | -16.87 |
| tangible asset value | 591424000 | 656070000 | -9.85 |
| net current asset value | 530928000 | 639247000 | -16.94 |
| invested capital | 558836000 | 671458000 | -16.77 |
| average receivables | 94603500 | 47672500 | 98.44 |
| average payables | 10923500 | 9543000 | 14.47 |
| average inventory | 17783500 | 15934063 | 11.61 |
| days sales outstanding | 89.62 | 110.16 | -18.64 |
| days payables outstanding | 123.87 | 185.6 | -33.26 |
| days of inventory on hand | 125.98 | 427.08 | -70.50 |
| receivables turnover | 4.07 | 3.31 | 22.92 |
| payables turnover | 2.95 | 1.97 | 49.83 |
| inventory turnover | 2.9 | 0.85 | 239.01 |
| roe | -0.24 | -0.39 | 39.54 |
| capex per share | 0.0 | 0.01 | -66.09 |
ROE: Return on Equity (ROE) increased to -0.24 on 2023-12-31 from -0.39 on 2022-12-31, representing a change of 39.54%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -49.16 on 2023-12-31 from -19.42 on 2022-12-31, representing a change of -153.14%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 5.41 on 2023-12-31 from 8.87 on 2022-12-31, representing a change of -39.03%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.03 on 2023-12-31 from 0.03 on 2022-12-31, representing a change of -6.25%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| ITCI | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 1.66 | 1.56 | 6.43 |
| net income per share | -0.25 | -0.16 | -59.15 |
| operating cash flow per share | -0.25 | 0.01 | -4899.27 |
| free cash flow per share | -0.26 | 0.0 | -5559.02 |
| cash per share | 9.52 | 9.88 | -3.67 |
| book value per share | 10.82 | 11.04 | -1.92 |
| tangible book value per share | 10.82 | 11.04 | -1.92 |
| shareholders equity per share | 10.82 | 11.04 | -1.92 |
| interest debt per share | 0.17 | 0.18 | -5.04 |
| market cap | 7739072803.62 | 7052127245.93 | 9.74 |
| enterprise value | 7292469803.62 | 6375359245.93 | 14.39 |
| pe ratio | -73.5 | -108.69 | 32.38 |
| price to sales ratio | 44.18 | 43.7 | 1.11 |
| pocfratio | -291.77 | 13011.3 | -102.24 |
| pfcf ratio | -284.31 | 14421.53 | -101.97 |
| pb ratio | 6.76 | 6.16 | 9.72 |
| ptb ratio | 6.76 | 6.16 | 9.72 |
| ev to sales | 41.63 | 39.5 | 5.39 |
| enterprise value over ebitda | -187.71 | -231.04 | 18.75 |
| ev to operating cash flow | -274.93 | 11762.66 | -102.34 |
| ev to free cash flow | -267.9 | 13037.54 | -102.05 |
| earnings yield | -0.0 | -0.0 | -47.89 |
| free cash flow yield | -0.0 | 0.0 | -5172.55 |
| debt to equity | 0.02 | 0.02 | -3.18 |
| debt to assets | 0.01 | 0.01 | -3.45 |
| net debt to ebitda | 11.5 | 24.53 | -53.13 |
| current ratio | 7.66 | 7.81 | -2.04 |
| interest coverage | 0 | 0 | NaN |
| income quality | 1.01 | -0.03 | 3115.47 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0.38 | 0.35 | 9.58 |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.03 | 0.1 | -126.83 |
| capex to revenue | 0.0 | 0.0 | 1109.96 |
| capex to depreciation | 5.04 | 0.41 | 1127.56 |
| stock based compensation to revenue | 0.1 | 0.1 | -1.56 |
| graham number | 7.79 | 6.23 | 24.94 |
| roic | -0.03 | -0.02 | -41.69 |
| return on tangible assets | -0.02 | -0.01 | -61.81 |
| graham net net | 8.96 | 9.33 | -3.98 |
| working capital | 1105618000 | 1102476000 | 0.28 |
| tangible asset value | 1144826000 | 1144612000 | 0.02 |
| net current asset value | 1092112000 | 1088359000 | 0.34 |
| invested capital | 1121634000 | 1118428000 | 0.29 |
| average receivables | 145661000 | 138435500 | 5.22 |
| average payables | 13943000 | 14540000 | -4.11 |
| average inventory | 21810500 | 18015500 | 21.07 |
| days sales outstanding | 74.82 | 81.26 | -7.93 |
| days payables outstanding | 60.8 | 139.1 | -56.29 |
| days of inventory on hand | 138.43 | 159.18 | -13.04 |
| receivables turnover | 1.2 | 1.11 | 8.61 |
| payables turnover | 1.48 | 0.65 | 128.80 |
| inventory turnover | 0.65 | 0.57 | 14.99 |
| roe | -0.02 | -0.01 | -62.26 |
| capex per share | 0.01 | 0.0 | 1187.81 |
ROE: Return on Equity (ROE) decreased to -0.02 on 2024-09-30 Q3 from -0.01 on 2024-06-30 Q2, representing a change of -62.26%. Suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio decreased to 7.66 on 2024-09-30 Q3 from 7.81 on 2024-06-30 Q2, representing a change of -2.04%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -73.50 on 2024-09-30 Q3 from -108.69 on 2024-06-30 Q2, representing a change of 32.38%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.02 on 2024-09-30 Q3 from 0.02 on 2024-06-30 Q2, representing a change of -3.18%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
None
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2025-01-16 12:10:00
NEW YORK , Jan. 16, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Enfusion, Inc. (NYSE: ENFN)'s sale to Clearwater Analytics for $5.85 per share in cash and $5.40 per share in Clearwater Class A Common Stock. If you are an Enfusion shareholder, click here to learn more about your rights and options.
Sentiment: Positive
Publish Date: 2025-01-14 09:56:09
JNJ is set to acquire ITCI for $132 per share in cash. The transaction is likely to close before this year's end.
Sentiment: Positive
Publish Date: 2025-01-14 08:01:36
Intra-Cellular (ITCI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Sentiment: Positive
Publish Date: 2025-01-13 18:38:00
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Intra-Cellular Therapies, Inc. (NasdaqGS: ITCI) to Johnson & Johnson (NYSE: JNJ). Under the terms of the proposed transaction, shareholders of Intra-Cellular will receive $132.00 in cash for each share of Intra-Cellular that they own. KSF is seeking to determine whether this consideration and the process t.
Sentiment: Positive
Publish Date: 2025-01-13 18:15:00
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Intra-Cellular Therapies (Nasdaq: ITCI) for possible breaches of fiduciary duty and other violations of law in its transaction with Johnson & Johnson. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Intra-Cellular Therapies stockholders will receive only $132.00 per share in cash.
Sentiment: Negative
Publish Date: 2025-01-13 14:23:32
Intra-Cellular +32.49 (+34.25%) Johnson & Johnson +2.22 (+1.56%)
Sentiment: Positive
Publish Date: 2025-01-13 12:41:30
Intra-Cellular stock gains 15% as it settles Caplyta patent litigation with Sandoz protecting the drug's exclusivity in the United States till July 1, 2040.
Sentiment: Positive
Publish Date: 2025-01-13 12:07:32
Drugmakers signed deals worth at least $18 billion in combined value on Monday, the first day of the healthcare industry's top conference in San Francisco.
Sentiment: Neutral
Publish Date: 2025-01-13 09:58:32
Intra-Cellular +32.2 (+33.94%) Johnson & Johnson +1.38 (+0.97%)
Sentiment: Positive
Publish Date: 2025-01-13 09:25:48
Shares of Intra-Cellular Therapies (ITCI) are surging 35% in premarket trading Monday after Johnson & Johnson (JNJ) said it will acquire the biopharmaceutical company for roughly $14.6 billion.
Sentiment: Positive
Publish Date: 2025-01-13 08:06:00
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) to Johnson & Johnson for $132.00 per share in cash is fair to Intra-Cellular shareholders. Halper Sadeh encourages Intra-Cellular shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation.
Sentiment: Neutral
Publish Date: 2025-01-13 06:56:20
Intra-Cellular (ITCI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Sentiment: Neutral
Publish Date: 2025-01-13 06:38:07
Johnson & Johnson said on Monday it would buy drugmaker Intra-Cellular Therapies for about $14.6 billion, boosting its presence in the market for neurological disorder treatments.
Sentiment: Positive
Publish Date: 2025-01-13 06:32:00
Acquisition includes CAPLYTA ® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of schizophrenia in adults
Sentiment: Positive
Publish Date: 2025-01-13 06:30:00
NEW BRUNSWICK, N.J. & BEDMINSTER, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) and Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) announced today that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Intra-Cellular Therapies, a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, for $132.00 per share in cash for a total equity value.
Sentiment: Neutral
Publish Date: 2025-01-13 04:16:04
Johnson & Johnson (NYSE:JNJ) is reportedly in talks to acquire neuroscience-focused biotech firm Intra-Cellular Therapies for $10bn. If completed, the deal would mark the largest biotech acquisition since Pfizer's $43bn purchase of Seagen in 2023.
Sentiment: Neutral
Publish Date: 2025-01-12 16:35:42
Johnson & Johnson is exploring a bid to acquire Intra-Cellular Therapies Inc , a biopharmaceutical company, Bloomberg News reported on Sunday citing people familiar with the matter.
Sentiment: Positive
Publish Date: 2025-01-10 06:30:00
BEDMINSTER, N.J., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with Sandoz Inc. (Sandoz) resolving patent litigation related to Intra-Cellular Therapies' product CAPLYTA® (lumateperone). The litigation, which is pending in the U.S. District Court for the District of New Jersey, resulted from submission by Sandoz of an Abbreviated New Drug Application to the U.S. Food and Drug Administration seeking approval to market a generic equivalent of CAPLYTA in the United States. The settlement agreement permits Sandoz to begin selling generic versions of CAPLYTA on July 1, 2040, or earlier under certain circumstances. As required by law, Intra-Cellular Therapies will submit the agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice. Similar patent litigation brought by Intra-Cellular Therapies against other parties remains pending in the U.S. District Court for the District of New Jersey.
Sentiment: Positive
Publish Date: 2025-01-06 08:00:00
BEDMINSTER, N.J., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 11:15 a.m. PT in San Francisco, CA.
Sentiment: Negative
Publish Date: 2024-12-11 08:00:00
Presentations complement topline data with new data from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy for the treatment of major depressive disorder
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
